leflunomide has been researched along with celecoxib in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Arriola, ER; Lee, NP | 1 |
| Infante, R; Lahita, RG | 1 |
| Chong, BS; Lowder, DM; Luong, BT | 1 |
| Simon, LS; Yocum, D | 1 |
| Wasko, MC; Wildy, KS | 1 |
| Amenitsch, H; Baldelli Bombelli, F; Haataja, JS; Maiolo, D; Metrangolo, P; Michelet, C; Pigliacelli, C; Sánchez Moreno, P; Tirotta, I | 1 |
6 review(s) available for leflunomide and celecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Treatment advances in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Male; Prognosis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Treatment Outcome | 1999 |
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Male; Middle Aged; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Sulfones | 2000 |
Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drug Interactions; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides | 2000 |
New and future drug therapies for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; CD40 Antigens; Celecoxib; Etanercept; Forecasting; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides | 2000 |
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones | 2001 |
5 other study(ies) available for leflunomide and celecoxib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Efficient Encapsulation of Fluorinated Drugs in the Confined Space of Water-Dispersible Fluorous Supraparticles.
Topics: Alkynes; Benzoxazines; Celecoxib; Cyclopropanes; Fluorine; Gold; Halogenation; Leflunomide; Macromolecular Substances; Metal Nanoparticles; Particle Size; Water | 2017 |